Novartis Transfers Lucentis and Beovu Rights to CMS Vision in China Deal
Novartis (NYSE: NVS) announced on October 27, 2025, the signing of a strategic cooperation agreement...
SGX: 8A8
Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology
On September 12, 2025, Jingze Biopharmaceutical (Hefei) Co., Ltd., based in China, and a subsidiary...
AccurEdit Therapeutics Raises $75 M Series A, Secures Strategic Partners for Gene‑Editing Platform
China‑based AccurEdit Therapeutics (Suzhou) Co., Ltd. announced that it has closed a US$75 million Series A financing...
Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS
China‑based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd....
China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment
China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...